This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Ariad Pharma Falls On Weak Leukemia Drug Prescriptions

Ariad expects to complete enrollment by the end of the year in a study comparing Iclusig to Gleevec in first-line CML patients. The company believes positive results will help convince doctors to use Iclusig with newly diagnosed CML patients. Ariad shorts, including the aforementioned fund manager, believe this study will fail and may even be stopped early because Inclusig's safety and tolerability will be significantly worse than Gleevec.

On Wednesday, BMO Capital Markets analyst Jim Birchenough reiterated his outperform rating on Ariad and defended the company's outlook following a conversation with CEO Harvey Berger. Here's what Birchenough told his clients:

We had the opportunity to talk with Ariad's CEO Dr. Harvey Berger late yesterday to review recent concerns regarding IMS prescription data for ICLUSIG, breadth of proposed ICLUSIG labeling in the EU, and expectations for ALK/EGFR inhibitor AP26113 in NSCLC. Importantly, while the shares have been under pressure on this week's IMS TRX data, Dr. Berger highlighted good visibility on ICLUSIG daily data to the patient level, confidence in continued launch momentum, and breadth of ICLUSIG use across community and academic centers, by line of therapy and independent of mutation status. Dr. Berger acknowledged that the EU indication for 2nd -line ICLUSIG use after 2nd -generation TKI's was narrower than in the US, but highlighted 40% of front-line EU patients treated with 2nd -generation TKI's. Finally, with additional focus on ALK/EGFR inhibitor AP26113, Dr. Berger highlighted activity in brain metastases as key for favorable positioning in ALK+ patients where 50% of XALKORI failures have brain metastases, and importantly confidence in a similarly deliberate process of dose optimization to achieve blood levels that should consistently inhibit EGFR mutations in patients selected for proximal Tarceva failure in the phase 2 expansion study.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ARIA $8.39 0.00%
BMY $65.26 0.00%
NVS $100.40 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs